...
首页> 外文期刊>Stem cells translational medicine. >Human Cartilage-Derived Progenitor Cells From Committed Chondrocytes for Efficient Cartilage Repair and Regeneration
【24h】

Human Cartilage-Derived Progenitor Cells From Committed Chondrocytes for Efficient Cartilage Repair and Regeneration

机译:来自犯罪软骨细胞的人类软骨衍生的祖细胞,用于高效软骨修复和再生

获取原文
   

获取外文期刊封面封底 >>

       

摘要

Articular cartilage is not a physiologically self-renewing tissue. Injury of cartilage often progresses from the articular surface to the subchondral bone, leading to pathogenesis of tissue degenerative diseases, such as osteoarthritis. Therapies to treat cartilage defects using autologous chondrocyte-based tissue engineering have been developed and used for more than 20 years; however, the challenge of chondrocyte expansion in vitro remains. A promising cell source, cartilage stem/progenitor cells (CSPCs), has attracted recent attention. Because their origin and identity are still unclear, the application potential of CSPCs is under active investigation. Here we have captured the emergence of a group of stem/progenitor cells derived from adult human chondrocytes, highlighted by dynamic changes in expression of the mature chondrocyte marker, COL2, and mesenchymal stromal/stem cell (MSC) marker, CD146. These cells are termed chondrocyte-derived progenitor cells (CDPCs). The stem cell-like potency and differentiation status of CDPCs were determined by physical and biochemical cues during culture. A low-density, low-glucose 2-dimensional culture condition (2DLL) was critical for the emergence and proliferation enhancement of CDPCs. CDPCs showed similar phenotype as bone marrow mesenchymal stromal/stem cells but exhibited greater chondrogenic potential. Moreover, the 2DLL-cultured CDPCs proved efficient in cartilage formation both in vitro and in vivo and in repairing large knee cartilage defects (6–13 cm2) in 15 patients. These findings suggest a phenotype conversion between chondrocytes and CDPCs and provide conditions that promote the conversion. These insights expand our understanding of cartilage biology and may enhance the success of chondrocyte-based therapies.Injury of cartilage, a non-self-repairing tissue, often progresses to pathogenesis of degenerative joint diseases, such as osteoarthritis. Although tissue-derived stem cells have been shown to contribute to tissue renewal and homeostasis, the derivation, biological function, and application potential of stem/progenitor cells found in adult human articular cartilage are incompletely understood. This study reports the derivation of a population of cartilage stem/progenitor cells from fully differentiated chondrocytes under specific culture conditions, which have the potential to reassume their chondrocytic phenotype for efficient cartilage regeneration. These findings support the possibility of using in vitro amplified chondrocyte-derived progenitor cells for joint cartilage repair.
机译:关节软骨不是生理学上自我更新组织。软骨损伤通常从关节面向骨髓内骨进行,导致组织退行性疾病的发病机制,如骨关节炎。使用基于自体的软骨细胞基组织工程治疗软骨缺陷的疗法已经开发并使用了20多年;然而,软骨细胞膨胀在体外的挑战仍然存在。有前途的细胞源,软骨茎/祖细胞(CSPC)吸引了最近的关注。因为他们的起源和身份尚不清楚,CSPCS的应用潜力正在积极调查。在这里,我们捕获了来自成年人软骨细胞的一组茎/祖细胞的出现,通过成熟软骨细胞标记物,COL2和间充质基质/干细胞(MSC)标记,CD146的动态变化来突出。这些细胞被称为软骨细胞衍生的祖细胞(CDPC)。 CDPC的干细胞状效力和分化状态由培养过程中的物理和生化线索测定。低密度,低葡萄糖的二维培养条件(2DLL)对于CDPC的出苗和增殖而言至关重要。 CDPCs显示与骨髓间充质基质/干细胞相似的表型,但表现出更大的软骨内潜力。此外,2DLL培养的CDPC在体外和体内既有高效的效率,在15名患者中修复大膝关节软骨缺陷(6-13cm 2)。这些发现表明软骨细胞和CDPC之间的表型转化,并提供促进转化的条件。这些见解扩大了我们对软骨生物学的理解,并可提高基于软骨细胞的治疗的成功。软骨,非修复组织的尿液,通常对退行性关节疾病的发病机制,如骨关节炎。尽管已显示组织衍生的干细胞对组织更新和稳态,但是在成人人关节软骨中发现的茎/祖细胞的衍生物,生物学功能和应用潜力被不完全理解。本研究报告了在特定的培养条件下从完全分化的软骨细胞中衍生软骨茎/祖细胞群,这具有潜力来重新组织软骨表型以获得有效的软骨再生。这些发现支持使用体外扩增的软骨细胞衍生的祖细胞进行关节软骨修复。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号